The University of Texas MD Anderson Cancer Center plans to expand its global oncology efforts in Mozambique and Brazil, including a new four-year agreement to broaden existing cancer prevention and treatment efforts with the Ministry of Health in Mozambique and a $5.1 million grant from NIH focused on cervical cancer prevention and treatment among women living with the human immunodeficiency virus.
A study led by researchers at The University of Texas MD Anderson Cancer Center demonstrates that a loss of metabolic fitness in chimeric antigen receptor (CAR) natural killer (NK) cells is a critical mechanism of resistance, with infused cells gradually losing the ability to compete with tumor cells for nutrients, leading to tumor relapse.
MD Anderson Cancer Center and Nexo Therapeutics have entered a multi-year strategic collaboration that aligns the technology and capabilities of each organization at the earliest stages of drug discovery and development, with the aim of advancing cancer therapies against previously undruggable targets.
MD Anderson Cancer Center and New Orleans-based Ochsner Health are partnering to create Ochsner MD Anderson Cancer Center in southeastern Louisiana.Â
MD Anderson Cancer Center and Generate:Biomedicines formed a strategic collaboration to jointly discover and co-develop protein therapeutics for up to five oncology targets in advanced cancers, including small-cell and non-small-cell lung cancer.
The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a phase I trial led by researchers at MD Anderson Cancer Center. The first-in-human study was presented today at the 2023 American Association for Cancer Research annual meeting.
MD Anderson Cancer Center researchers have identified recent developments in effective combination therapies for patients with BRAF V600E mutations, an approach to identify cancer biomarkers in extracellular vesicles, therapeutic strategies for improving treatment responses in non-small cell lung cancer, and a novel combination therapy to overcome treatment resistance in a subset of patients with acute myeloid leukemia.
By investigating non-antibiotic-disrupted microbiomes, MD Anderson Cancer Center researchers developed a machine-learning algorithm that can predict long-term response to CAR T therapy using microbiome-based biomarkers. The study was published in Nature Medicine.
Kerin Adelson was named chief quality and value officer at MD Anderson Cancer Center.
MD Anderson Cancer Center and the Hospital Alejandro Otero Lopez-Manati Medical Center of Manati, Puerto Rico, received the 2023 the DeWitt C. Baldwin, Jr. Award.Â
